PUBLISHER: Polaris Market Research | PRODUCT CODE: 1786976
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1786976
U.S. Blood-Based Biomarker for Parkinson's Disease Market Size, Share, Industry Analysis Report By Biomarker Type, By Application, By Technology Platform, By End User - Market Forecast, 2025-2034
The U.S blood-based biomarkers for Parkinson's disease market size is expected to reach USD 1,156.34 million by 2034, according to a new study by Polaris Market Research. The report "U.S. Blood-Based Biomarker for Parkinson's Disease Market Share, Size, Trends, Industry Analysis Report By Biomarker Type [Alpha-Synuclein (a-syn), Neurofilament Light Chain (Nfl)], By Application, By Technology Platform, By End User; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Blood-based biomarkers for Parkinson's disease refer to measurable biological molecules in the blood that aid in the early detection, diagnosis, and monitoring of disease progression and therapeutic responses. The U.S. blood-based biomarker for Parkinson's disease market is driven by the increasing focus on noninvasive diagnostic alternatives that offer improved patient compliance and reduce reliance on imaging techniques or cerebrospinal fluid analysis. This shift toward minimally invasive approaches is encouraging the development of highly sensitive and specific biomarker panels capable of identifying Parkinson's Disease in its preclinical stages, ultimately enabling earlier therapeutic intervention and improved disease management outcomes.
The growing integration of advanced omics technologies, such as proteomics and transcriptomic, into biomarker discovery workflows drives the expansion opportunities. These technologies are enhancing the identification of novel blood-based markers by enabling high-throughput screening and multi-dimensional data analysis. Omics-based insights are playing a crucial role in expanding the biomarker landscape and fostering the development of personalized diagnostics and treatment strategies tailored to individual patient profiles, as research continues to deepen the understanding of Parkinson's disease pathology.
U.S. Blood-Based Biomarker for Parkinson's Disease Market Report Highlights
In terms of application, the diagnostic biomarkers segment led revenue generation and was valued at USD 81.60 million in 2024, owing to their critical role in detecting Parkinson's during early/prodromal stages when intervention is most impactful.
Based on biomarker type, the NfL biomarker segment is projected to record the highest CAGR of 19.50% during the forecast period, owing to its established utility as a sensitive neurodegeneration indicator across multiple neurological disorders.
In terms of technology platform, the aSyn-SAA segment held a notable market share in 2024 due to its high sensitivity and specificity in detecting misfolded alpha-synuclein aggregates.
Based on end user, the pharmaceutical companies segment is projected to grow significantly during 2025-2034, driven by rising investments in disease-modifying therapies and personalized treatment development.
A few global key market players in the U.S. blood-based biomarker for Parkinson's disease market include Abbott Laboratories, Alamar Biosciences, Amprion, Biogen, C2N Diagnostics, Denali Therapeutics, Quanterix Corporation, SomaLogic, Thermo Fisher Scientific Inc., and Verily Life Sciences
Polaris Market Research has segmented the U.S. blood-based biomarker for Parkinson's disease market report on the basis of biomarker type, application, technology platform, and end user:
By Biomarker Type Outlook (Revenue, USD Million, 2020-2034)
Alpha-Synuclein (a-Syn)
Neurofilament Light Chain (NfL)
Inflammatory Markers
Metabolic Biomarkers
Others
By Application Outlook (Revenue, USD Million, 2020-2034)
Diagnostic Biomarkers
Prognostic Biomarkers
Monitoring Biomarkers
Therapeutic Response Biomarkers
Others
By Technology Platform Outlook (Revenue, USD Million, 2020-2034)
Alpha-Synuclein Seeding Amplification Assay (aSyn-SAA)
ELISA-Based Assays
Immunoassays
Mass Spectrometry
Others
By End User Outlook (Revenue, USD Million, 2020-2034)
Hospitals and Clinics
Diagnostic Laboratories
Research Institutes
Pharmaceutical Companies
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. U.S. Blood-Based Biomarker for Parkinson's Disease Market Insights
- 4.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market - Market Snapshot
- 4.2. U.S. Blood-Based Biomarker for Parkinson's Disease Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Prevalence of Parkinson's Disease
- 4.2.1.2. Advancements in Biomarker Discovery and Validation
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Lack of Standardization and Clinical Validation
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. U.S. Blood-Based Biomarker for Parkinson's Disease Market Trends
- 4.6. Value Chain Analysis
5. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Biomarker Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Biomarker Type, 2020-2034 (USD Billion)
- 5.3. Alpha-Synuclein (a-Syn)
- 5.3.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Alpha-Synuclein (a-Syn), by Region, 2020-2034 (USD Billion)
- 5.4. Neurofilament Light Chain (NfL)
- 5.4.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Neurofilament Light Chain (NfL), by Region, 2020-2034 (USD Billion)
- 5.5. Inflammatory Markers
- 5.5.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Inflammatory Markers, by Region, 2020-2034 (USD Billion)
- 5.6. Metabolic Biomarkers
- 5.6.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Metabolic Biomarkers, by Region, 2020-2034 (USD Billion)
- 5.7. Others
- 5.7.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Others, by Region, 2020-2034 (USD Billion)
6. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 6.3. Diagnostic Biomarkers
- 6.3.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Diagnostic Biomarkers, by Region, 2020-2034 (USD Billion)
- 6.4. Prognostic Biomarkers
- 6.4.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Prognostic Biomarkers, by Region, 2020-2034 (USD Billion)
- 6.5. Monitoring Biomarkers
- 6.5.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Monitoring Biomarkers, by Region, 2020-2034 (USD Billion)
- 6.6. Therapeutic Response Biomarkers
- 6.6.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Therapeutic Response Biomarkers, by Region, 2020-2034 (USD Billion)
- 6.7. Others
- 6.7.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Others, by Region, 2020-2034 (USD Billion)
7. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 7.3. Alpha-Synuclein Seeding Amplification Assay (aSyn-SAA)
- 7.3.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Alpha-Synuclein Seeding Amplification Assay (aSyn-SAA), by Region, 2020-2034 (USD Billion)
- 7.4. ELISA-Based Assays
- 7.4.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by ELISA-Based Assays, by Region, 2020-2034 (USD Billion)
- 7.5. Immunoassays
- 7.5.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Immunoassays, by Region, 2020-2034 (USD Billion)
- 7.6. Mass Spectrometry
- 7.6.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Mass Spectrometry, by Region, 2020-2034 (USD Billion)
- 7.7. Others
- 7.7.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Others, by Region, 2020-2034 (USD Billion)
8. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by End User
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 8.3. Hospitals and Clinics
- 8.3.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Hospitals and Clinics, by Region, 2020-2034 (USD Billion)
- 8.4. Diagnostic Laboratories
- 8.4.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Diagnostic Laboratories, by Region, 2020-2034 (USD Billion)
- 8.5. Research Institutes
- 8.5.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Research Institutes, by Region, 2020-2034 (USD Billion)
- 8.6. Pharmaceutical Companies
- 8.6.1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Pharmaceutical Companies, by Region, 2020-2034 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Abbott Laboratories
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Alamar Biosciences
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Amprion
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Biogen
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. C2N Diagnostics
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Denali Therapeutics
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Quanterix Corporation
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Verily Life Sciences
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. SomaLogic
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Thermo Fisher Scientific Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
List of Tables:
- Table 1 U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Biomarker Type, 2020-2034 (USD Billion)
- Table 2 U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- Table 3 U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- Table 4 U.S. Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
List of Figures:
- Figure 1. U.S. Blood-Based Biomarker for Parkinson's Disease Market, 2020-2034 (USD Billion)
- Figure 2. Integrated Ecosystem
- Figure 3. Research Methodology: Top-Down & Bottom-Up Price
- Figure 4. Porter's Five Forces
- Figure 5. Market by Biomarker Type
- Figure 6. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Biomarker Type, 2024 & 2034 (USD Billion)
- Figure 7. Market by Application
- Figure 8. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2024 & 2034 (USD Billion)
- Figure 9. Market by Technology Platform
- Figure 10. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2024 & 2034 (USD Billion)
- Figure 11. Market by End User
- Figure 12. U.S. Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2024 & 2034 (USD Billion)
- Figure 13. Strategic Analysis - U.S. Blood-Based Biomarker for Parkinson's Disease Market
